A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
for Non-alcoholic Fatty Liver Disease
Sites in Sarasota, Cape Coral +50 more locations
Sponsor: GlaxoSmithKline
Sex: All·Age: 18 - 75
Code: NCT07221188·Phase 3·Recruiting·Listed Oct 2025